StockData
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. (AMRX) stock

AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3072% above fair value
$21.88+0.76 (+3.60%)

Close on Nov 18, 2026Market cap $6.99BP/E 44.7Yield –

Amneal Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Amneal Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $127.84M, down 54.8% year over year. For fiscal 2025 it was $269.93M, up 11.0% from the year before. The highest annual figure on record is $322.56M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$269.93M+11.0%
FY2024Dec 31, 2024$243.18M-19.6%
FY2023Dec 31, 2023$302.36M+1517.5%
FY2022Dec 31, 2022$18.69M-90.4%
FY2021Dec 31, 2021$194.09M-39.8%
FY2020Dec 31, 2020$322.56M–
FY2019Dec 31, 2019-$45.48M-127.2%
FY2018Dec 31, 2018$167.14M+19.9%
FY2017Dec 31, 2017$139.42M–
FY2016Dec 31, 2016-$7.70M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$51.94M-185.2%
Q1 FY2026Mar 31, 2026-$34.92M–
Q4 FY2025Dec 31, 2025$108.54M+5.5%
Q3 FY2025Sep 30, 2025$106.15M-15.0%
Q2 FY2025Jun 30, 2025$60.99M+110.1%
Q1 FY2025Mar 31, 2025-$5.75M–
Q4 FY2024Dec 31, 2024$102.92M-18.3%
Q3 FY2024Sep 30, 2024$124.83M+79.0%
Q2 FY2024Jun 30, 2024$29.03M–
Q1 FY2024Mar 31, 2024-$13.61M-110.5%
Q4 FY2023Dec 31, 2023$125.96M–
Q3 FY2023Sep 30, 2023$69.73M-6.4%
Q2 FY2023Jun 30, 2023-$23.35M–
Q1 FY2023Mar 31, 2023$130.02M+18.7%
Q4 FY2022Dec 31, 2022-$34.76M-176.0%
Q3 FY2022Sep 30, 2022$74.47M+3.8%
Q2 FY2022Jun 30, 2022-$130.57M–
Q1 FY2022Mar 31, 2022$109.55M-19.7%
Q4 FY2021Dec 31, 2021$45.76M-40.1%
Q3 FY2021Sep 30, 2021$71.72M+112.3%
Q2 FY2021Jun 30, 2021-$59.74M-135.0%
Q1 FY2021Mar 31, 2021$136.35M+227.3%
Q4 FY2020Dec 31, 2020$76.43M–
Q3 FY2020Sep 30, 2020$33.78M-73.4%
Q2 FY2020Jun 30, 2020$170.69M+1705.7%
Q1 FY2020Mar 31, 2020$41.66M–
Q4 FY2019Dec 31, 2019-$55.41M-123.1%
Q3 FY2019Sep 30, 2019$126.88M+255.8%
Q2 FY2019Jun 30, 2019$9.45M–
Q1 FY2019Mar 31, 2019-$126.40M-1778.6%
Q4 FY2018Dec 31, 2018$239.63M–
Q3 FY2018Sep 30, 2018$35.66M-38.5%
Q2 FY2018Jun 30, 2018-$115.68M–
Q1 FY2018Mar 31, 2018$7.53M–
Q4 FY2017Dec 31, 2017-$24.62M–
Q3 FY2017Sep 30, 2017$57.97M–

More Amneal Pharmaceuticals figures

See a number that looks wrong?